Research

Hormonal

Tirzepatide 15 mg once weekly produces significantly greater fat mass reduction and total body weight loss compared to semaglutide 1 mg and placebo in people with type 2 diabetes, primarily driven by fat mass rather than fat-free mass changes.

If you have type 2 diabetes, tirzepatide 15 mg taken once weekly is more effective than semaglutide 1 mg for reducing body fat and total weight. The weight loss comes mainly from fat, preserving muscle mass better than placebo. This suggests that for T2D patients seeking significant fat loss, tirzepatide may be a superior pharmacological option to semaglutide.

GoodSupportsHIGH confidence
Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction... Body weight loss with tirzepatide was predominantly driven by fat mass reduction.
Tim Heise et al. · Diabetes Care · 2023

Why this rating

Randomized, double-blind, parallel-arm study with statistical significance, though sample size was not explicitly powered for secondary outcomes.

Source

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise et al. · Diabetes Care · 2023

DOI 10.2337/dc22-1710

rct · n=117Cited 180×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →